Compare Hilton Hotels Corporation Common Stock (HLT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.94 (market cap $73.63B), while Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 824.8× Inovio Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HLT | INO | |
|---|---|---|
Market Cap | $73.63B | $89.27M |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $2.87 |
52-Week Low | $256.75 | $1.05 |
Enterprise Value | $86.12B | $60.28M |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.94, up 0.82% with a bearish technical signal despite recent earnings beats. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though the P/E ratio of 49.38 suggests premium valuation. The stock faces headwinds from negative equity and rising debt-to-asset ratio, now at 73.88% for 2025. Analyst consensus remains bullish with a $343.40 price target, and recent news highlights earnings optimism ahead of Q2 2026 results.
Outlook: Strong travel demand and consistent earnings beats support growth, but high leverage and valuation pose risks. Opportunities include brand expansion and operational efficiency, while risks involve debt servicing and economic sensitivity. Investors should weigh analyst optimism against fundamental pressures.
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
